ADARx Owner Reports Preferred Stock Tied to 8.91M Shares
The reported Preferred Stock will automatically convert into common stock upon ADARx's IPO closing, without further consideration.
Rhea-AI Filing Summary
ADARx Pharmaceuticals, Inc. has three 10% owners reporting preferred holdings as of September 24, 2026. LAV Biosciences Fund V, L.P. reports Series A, B, B-1 and C holdings corresponding to 8,908,775, 1,667,469, 513,067 and 153,868 underlying common shares, respectively. LAV Fund VI, L.P. and LAV Fund VI Opportunities, L.P. each report 307,738 underlying common shares indirectly through Series C. The counts give effect to a 1-for-1.1717 reverse stock split basis; Preferred Stock converts automatically into common stock upon IPO closing without further consideration.
Insights
Analyzing...
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
LAV Biosciences Fund V, L.P., LAV Fund VI Opportunities, L.P., LAV Fund VI, L.P.
Role
10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock F1, F2 | -- | -- | -- |
| holding | Series B Preferred Stock F1, F2 | -- | -- | -- |
| holding | Series B-1 Preferred Stock F1, F2 | -- | -- | -- |
| holding | Series C Preferred Stock F1, F2 | -- | -- | -- |
| holding | Series C Preferred Stock F1, F3 | -- | -- | -- |
| holding | Series C Preferred Stock F1, F4 | -- | -- | -- |
Holdings After Transaction:
Series A Preferred Stock — 8,908,775 contracts (Direct);
Series B Preferred Stock — 1,667,469 contracts (Direct);
Series B-1 Preferred Stock — 513,067 contracts (Direct);
Series C Preferred Stock — 153,868 contracts (Direct);
Series C Preferred Stock — 307,738 contracts (Indirect, By LAV Fund VI, L.P.);
Series C Preferred Stock — 307,738 contracts (Indirect, By LAV Fund VI Opportunities, L.P.)
Footnotes (4)
- F1. Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") will automatically convert on a 1-for-1.1717 reverse stock split basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- F2. LAV GP V, L.P. is the general partner of LAV Biosciences Fund V, L.P. ("LAV Biosciences"). LAV Corporate V GP, Ltd. is the general partner of LAV GP V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate V GP, Ltd. By virtue of these relationships, LAV GP V, L.P., LAV Corporate V GP, Ltd. and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Biosciences.
- F3. Shares are held by LAV Fund VI, L.P. ("LAV Fund VI"). LAV GP VI, L.P. ("LAV GP VI") is the general partner of LAV Fund VI and LAV Corporate VI GP, Ltd. ("LAV Corporate VI GP") is the general partner of LAV GP VI., L.P. Dr. Yi Shi is the managing partner of LAV Corporate VI GP, Ltd. By virtue of these relationships, LAV GP VI, L.P., LAV Corporate VI GP, Ltd. and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Fund VI, L.P.
- F4. Shares are held by LAV Fund VI Opportunities, L.P. ("LAV Fund VI Opportunities"). LAV GP VI Opportunities, L.P. ("LAV GP VI Opportunities") is the general partner of LAV Fund VI Opportunities, L.P. and LAV Corporate VI GP Opportunities, Ltd. ("LAV Corporate VI GP") is the general partner of LAV GP VI Opportunities, L.P. Dr. Yi Shi is the managing partner of LAV Corporate VI GP Opportunities, Ltd. By virtue of these relationships, LAV GP VI Opportunities, L.P., LAV Corporate VI GP Opportunities, Ltd., and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Fund VI Opportunities., L.P.
Key Figures
Series A Preferred Stock underlying common shares: 8,908,775 shares
Series B Preferred Stock underlying common shares: 1,667,469 shares
Series B-1 Preferred Stock underlying common shares: 513,067 shares
+4 more
7 metrics
Series A Preferred Stock underlying common shares
8,908,775 shares
LAV Biosciences Fund V, L.P.; as of September 24, 2026
Series B Preferred Stock underlying common shares
1,667,469 shares
LAV Biosciences Fund V, L.P.; as of September 24, 2026
Series B-1 Preferred Stock underlying common shares
513,067 shares
LAV Biosciences Fund V, L.P.; as of September 24, 2026
Series C Preferred Stock underlying common shares
153,868 shares
LAV Biosciences Fund V, L.P.; as of September 24, 2026
Indirect Series C Preferred Stock underlying common shares
307,738 shares
Held by LAV Fund VI, L.P.; as of September 24, 2026
Indirect Series C Preferred Stock underlying common shares
307,738 shares
Held by LAV Fund VI Opportunities, L.P.; as of September 24, 2026
Conversion basis
1-for-1.1717 reverse stock split basis
Preferred Stock automatically converts upon closing of the initial public offering
Key Terms
automatically convert, reverse stock split basis, initial public offering, without payment of further consideration
4 terms
automatically convert technical
"will automatically convert on a 1-for-1.1717 reverse stock split basis"
reverse stock split basis financial
"on a 1-for-1.1717 reverse stock split basis into shares of Common Stock"
initial public offering financial
"upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
without payment of further consideration financial
"without payment of further consideration"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
